Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 54: 611, 2008; 10.1373/clinchem.2007.101899
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shamburek, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Shamburek, R.
Related Collections
Right arrow Clinical Case Studies
(Clinical Chemistry. 2008;54:611.)
© 2008 American Association for Clinical Chemistry, Inc.

Commentaries

Commentary

Robert Shamburek

National Institutes of Health, Bethesda, MD.

Address correspondence to the author at: Bldg 10 7N115, 10 Center Drive, National Institutes of Health, Bethesda, MD, 20892-1666. Fax: 301-402-0190; e-mail bobs@nhlbi.nih.gov.

The first 20% of the full text of this article appears below.

Clinical laboratories typically focus on apolipoprotein (apo)E typing of polymorphisms (E2, E3, E4) and less on apoE concentrations, because increased apoE is found in hypertriglyceridemia but correlates less with coronary heart disease. The role of apoE and the importance of splenic macrophages in lipoprotein metabolism are highlighted by this case.

Type III hyperlipoproteinemia (HLP) is inherited either in a recessive or dominant . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Association for Clinical Chemistry.